T Cell News and Research

Latest T Cell News and Research

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

New data indicates that most microbes behave similarly on Earth and International Space Station

New data indicates that most microbes behave similarly on Earth and International Space Station

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Space Aging study may help identify novel genes linked to longevity

Space Aging study may help identify novel genes linked to longevity

FLI invites scientific elite to EKF Symposium on Adult Stem Cells in Aging, Diseases and Cancer

FLI invites scientific elite to EKF Symposium on Adult Stem Cells in Aging, Diseases and Cancer

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Palbociclib drug shows promise in women with HR+ metastatic breast cancer

Palbociclib drug shows promise in women with HR+ metastatic breast cancer

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.